Showing 8671-8680 of 10817 results for "".
- New RNA Monitoring Method May Allow for Early Diagnosis of AD in Infantshttps://practicaldermatology.com/news/new-rna-monitoring-method-may-allow-for-early-diagnosis-of-ad-in-infants/2461771/A novel monitoring method that enables human skin transcriptome analysis of the mRNA in sebum) collected from the skin using a simple oil-blotting film may help diagnose atopic dermatitis earlier than is currently possible. According to a newstudy
- Crown Laboratories Opens Expanded Production Facilityhttps://practicaldermatology.com/news/crown-laboratories-opens-expanded-production-facility/2461769/Crown Laboratories completed a 60,000-square-foot expansion at its manufacturing complex in Johnson City, Tennessee. A year in the making, the $7.5 million expansion project at Lafe Cox Drive increases manufacturing and warehouse space to support business growth. The appr
- HEROES Educational Campaign Highlights Role of Salons in Promoting Skin and Scalp Healthhttps://practicaldermatology.com/news/heroes-educational-campaign-highlights-role-of-salons-in-promoting-skin-and-scalp-health/2461766/The Globa
- ASA Awards: Jon M. Hanifin, MD, Wins David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/asa-awards-jon-m-hanifin-md-wins-david-martin-carter-mentor-award/2461728/The American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan. <
- Nielsen BioSciences, Maruho Co. Ltd. Enter License Agreement for the Treatment of Common Wartshttps://practicaldermatology.com/news/nielsen-biosciences-maruho-co-ltd-enter-license-agreement-for-the-treatment-of-common-warts/2461719/Nielsen BioSciences, Inc.</
- News You Can Use: MIPS Hardship Exception Available Nowhttps://practicaldermatology.com/news/news-you-can-use-mips-hardship-exception-available-now/2461702/Physicians may now apply for an Extreme and Uncontrollable Circumstances hardship exception to avoid an up to 9% penalty in the Merit-based Incentive Payment System (MIPS) thanks to advocacy from the American Medical Association and organized medicine about the ongoing impacts of the COVID-19 pub
- Online Exclusive: New Practice-changing Research Links ARD to Bacteriahttps://practicaldermatology.com/news/online-exclusive-new-practice-changing-research-links-rad-to-bacteria/2461701/As many as 95% of people undergoing radiation treatment for cancer will develop acute radiation dermatitis (ARD). Little, however, has been known about why this condition occurs, and there are no widely adapted or standardized treatments for preventing severe ARD. New research may chang
- Positive Results Seen for Alphyn’s AB-101 in Kids with ADhttps://practicaldermatology.com/news/positive-pediatric-results-seen-for-alphyns-ab-101-in-ad/2461700/
- PathologyWatch Launches ‘Show Me Some Skin’ Campaign for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/pathologywatch-launches-show-me-some-skin-campaign-for-skin-cancer-awareness-month/2461696/
- Aquavit News: Company Files Investigational New Drug Application for Dermatoxhttps://practicaldermatology.com/news/aquavit-news-company-files-investigational-new-drug-application-for-dermatox/2461687/Aquavit has filed an Investigational New Drug Application with the U.S Food and Drug Administration (FDA) for Dermatox (aqubotulinumtoxinA), their intradermal injection of botulinum toxin. AqubotulinumtoxinA has already received regulatory approvals in Asia, Sou